Showing results (1731-1740 of 2,276) with videos related to
Sort By:
Pageof 228
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2009
Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cellsXueli Yuan, M Javeed Ansari, Francesca D'Addio, et al.Physical Review Letters|October 10, 2006
Isospin symmetry of odd-odd mirror nuclei: identification of excited states in N=Z-2 48MnM A Bentley, C Chandler, M J Taylor, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 3, 2016
LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 DownregulationAlba Llibre, Constantino López-Macías, Teresa Marafioti, et al.Cancer Research|September 15, 2017
PD-1 Status in CD8<sup>+</sup> T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck CancerBenjamin A Kansy, Fernando Concha-Benavente, Raghvendra M Srivastava, et al.Oncotarget|September 23, 2016
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumorsYu Mei, Wenya Linda Bi, Noah F Greenwald, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivoJun Yang, Leonardo V Riella, Susanne Chock, et al.Molecular Therapy Oncolytics|February 4, 2022
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse modelYufei Wang, Alicia Buck, Marion Grimaud, et al.Frontiers in Immunology|March 31, 2022
The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental SettingsStinne R Greisen, Tue W Kragstrup, Jesper Skovhus Thomsen, et al.Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUNAbdallah Flaifel, Wanling Xie, David A Braun, et al.Pageof 228